(Q39512157)

12 September 2017

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models (English)

1 reference

non-small-cell lung carcinoma

12 September 2017

1 reference

1 reference

Mi Young Cha

1

1 reference

12 September 2017

Kwang-Ok Lee

2

1 reference

12 September 2017

Mira Kim

3

1 reference

12 September 2017

Ji Yeon Song

4

1 reference

12 September 2017

Kyu Hang Lee

5

1 reference

12 September 2017

Jongmin Park

6

1 reference

12 September 2017

Yun Jung Chae

7

1 reference

12 September 2017

Young Hoon Kim

8

1 reference

12 September 2017

Kwee Hyun Suh

9

1 reference

12 September 2017

Gwan Sun Lee

10

1 reference

12 September 2017

Seung Bum Park

11

1 reference

12 September 2017

Maeng Sup Kim

12

1 reference

12 September 2017

language of work or name

English

0 references

publication date

24 August 2011

1 reference

International Journal of Cancer

12 September 2017

1 reference

12 September 2017

130

1 reference

12 September 2017

2445-2454

1 reference

12 September 2017

10

1 reference

Cell signaling by receptor tyrosine kinases

12 September 2017

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

21 January 2018

1 reference

Tyrosine kinase inhibitors: from rational design to clinical trials

21 January 2018

1 reference

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

Quantitative prediction of fold resistance for inhibitors of EGFR.

21 January 2018

1 reference

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

21 January 2018

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification

21 January 2018

1 reference

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

21 January 2018

1 reference

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor

21 January 2018

1 reference

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

21 January 2018

1 reference

Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer

21 January 2018

1 reference

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

21 January 2018

1 reference

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

21 January 2018

1 reference

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26276

1 reference

release_6yfwxtpcpjddfdr526sr34tnhe

12 September 2017

0 references

1 reference